Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

ESC heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34544205
ESC Heart Fail. 2021 Sep 20; doi: 10.1002/ehf2.13622. Epub 2021 Sep 20.

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim...

Cite
Kolwelter J, Bosch A, Jung S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;doi: 10.1002/ehf2.13622.
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, . https://doi.org/10.1002/ehf2.13622
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC heart failure vol. (2021). doi: https://doi.org/10.1002/ehf2.13622
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021 Sep 20; doi: 10.1002/ehf2.13622. Epub 2021 Sep 20. PMID: 34544205.
Copy Download .nbib Format: NLM
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.

Cardiovascular diabetology

Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE.
PMID: 34481498
Cardiovasc Diabetol. 2021 Sep 04;20(1):178. doi: 10.1186/s12933-021-01358-8.

BACKGROUND: Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.METHODS: Patients (N = 97) with type 2 diabetes were randomized to...

Cite
Ott C, Jung S, Korn M, et al. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021;20(1):178doi: 10.1186/s12933-021-01358-8.
Ott, C., Jung, S., Korn, M., Kannenkeril, D., Bosch, A., Kolwelter, J., Striepe, K., Bramlage, P., Schiffer, M., & Schmieder, R. E. (2021). Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovascular diabetology, 20(1), 178. https://doi.org/10.1186/s12933-021-01358-8
Ott, Christian, et al. "Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine." Cardiovascular diabetology vol. 20,1 (2021): 178. doi: https://doi.org/10.1186/s12933-021-01358-8
Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021 Sep 04;20(1):178. doi: 10.1186/s12933-021-01358-8. PMID: 34481498; PMCID: PMC8418746.
Copy Download .nbib Format: NLM
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.

Cardiovascular diabetology

Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R.
PMID: 34991562
Cardiovasc Diabetol. 2022 Jan 06;21(1):4. doi: 10.1186/s12933-021-01436-x.

BACKGROUND: In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on L-arginine (Arg) related risk markers asymmetric and symmetric dimethylarginine (ADMA and SDMA) and...

Cite
Gessner A, Gemeinhardt A, Bosch A, et al. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022;21(1):4doi: 10.1186/s12933-021-01436-x.
Gessner, A., Gemeinhardt, A., Bosch, A., Kannenkeril, D., Staerk, C., Mayr, A., Fromm, M. F., Schmieder, R. E., & Maas, R. (2022). Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular diabetology, 21(1), 4. https://doi.org/10.1186/s12933-021-01436-x
Gessner, Arne, et al. "Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers." Cardiovascular diabetology vol. 21,1 (2022): 4. doi: https://doi.org/10.1186/s12933-021-01436-x
Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022 Jan 06;21(1):4. doi: 10.1186/s12933-021-01436-x. PMID: 34991562.
Copy Download .nbib Format: NLM
Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome.

Journal of the Endocrine Society

Kannankeril J, Carroll T, Findling JW, Javorsky B, Gunsolus IL, Phillips J, Raff H.
PMID: 32935666
J Endocr Soc. 2020 Jul 24;4(10):bvaa107. doi: 10.1210/jendso/bvaa107. eCollection 2020 Oct 01.

CONTEXT: Late-night salivary cortisol (LNSC) measured by enzyme immunoassay (EIA-F) is a first-line screening test for Cushing syndrome (CS) with a reported sensitivity and specificity of >90%. However, liquid chromatography-tandem mass spectrometry, validated to measure salivary cortisol (LCMS-F) and...

Cite
Kannankeril J, Carroll T, Findling JW, et al. Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome. J Endocr Soc. 2020;4(10):bvaa107doi: 10.1210/jendso/bvaa107.
Kannankeril, J., Carroll, T., Findling, J. W., Javorsky, B., Gunsolus, I. L., Phillips, J., & Raff, H. (2020). Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome. Journal of the Endocrine Society, 4(10), bvaa107. https://doi.org/10.1210/jendso/bvaa107
Kannankeril, Joshua, et al. "Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome." Journal of the Endocrine Society vol. 4,10 (2020): bvaa107. doi: https://doi.org/10.1210/jendso/bvaa107
Kannankeril J, Carroll T, Findling JW, Javorsky B, Gunsolus IL, Phillips J, Raff H. Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome. J Endocr Soc. 2020 Jul 24;4(10):bvaa107. doi: 10.1210/jendso/bvaa107. eCollection 2020 Oct 01. PMID: 32935666; PMCID: PMC7480956.
Copy Download .nbib Format: NLM
Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation.

Hypertension (Dallas, Tex. : 1979)

Lugo-Gavidia LM, Burger D, Matthews VB, Nolde JM, Galindo Kiuchi M, Carnagarin R, Kannenkeril D, Chan J, Joyson A, Herat LY, Azzam O, Schlaich MP.
PMID: 33979187
Hypertension. 2021 Jun;77(6):1825-1844. doi: 10.1161/HYPERTENSIONAHA.121.16975. Epub 2021 May 12.

[Figure: see text].

Cite
Lugo-Gavidia LM, Burger D, Matthews VB, et al. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021;77(6):1825-1844doi: 10.1161/HYPERTENSIONAHA.121.16975.
Lugo-Gavidia, L. M., Burger, D., Matthews, V. B., Nolde, J. M., Galindo Kiuchi, M., Carnagarin, R., Kannenkeril, D., Chan, J., Joyson, A., Herat, L. Y., Azzam, O., & Schlaich, M. P. (2021). Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension (Dallas, Tex. : 1979), 77(6), 1825-1844. https://doi.org/10.1161/HYPERTENSIONAHA.121.16975
Lugo-Gavidia, Leslie Marisol, et al. "Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation." Hypertension (Dallas, Tex. : 1979) vol. 77,6 (2021): 1825-1844. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.16975
Lugo-Gavidia LM, Burger D, Matthews VB, Nolde JM, Galindo Kiuchi M, Carnagarin R, Kannenkeril D, Chan J, Joyson A, Herat LY, Azzam O, Schlaich MP. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021 Jun;77(6):1825-1844. doi: 10.1161/HYPERTENSIONAHA.121.16975. Epub 2021 May 12. PMID: 33979187.
Copy Download .nbib Format: NLM
Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation.

Hypertension (Dallas, Tex. : 1979)

Lugo-Gavidia LM, Burger D, Matthews VB, Nolde JM, Galindo Kiuchi M, Carnagarin R, Kannenkeril D, Chan J, Joyson A, Herat LY, Azzam O, Schlaich MP.
PMID: 33979187
Hypertension. 2021 Jun;77(6):1825-1844. doi: 10.1161/HYPERTENSIONAHA.121.16975. Epub 2021 May 12.

[Figure: see text].

Cite
Lugo-Gavidia LM, Burger D, Matthews VB, et al. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021;77(6):1825-1844doi: 10.1161/HYPERTENSIONAHA.121.16975.
Lugo-Gavidia, L. M., Burger, D., Matthews, V. B., Nolde, J. M., Galindo Kiuchi, M., Carnagarin, R., Kannenkeril, D., Chan, J., Joyson, A., Herat, L. Y., Azzam, O., & Schlaich, M. P. (2021). Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension (Dallas, Tex. : 1979), 77(6), 1825-1844. https://doi.org/10.1161/HYPERTENSIONAHA.121.16975
Lugo-Gavidia, Leslie Marisol, et al. "Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation." Hypertension (Dallas, Tex. : 1979) vol. 77,6 (2021): 1825-1844. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.16975
Lugo-Gavidia LM, Burger D, Matthews VB, Nolde JM, Galindo Kiuchi M, Carnagarin R, Kannenkeril D, Chan J, Joyson A, Herat LY, Azzam O, Schlaich MP. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021 Jun;77(6):1825-1844. doi: 10.1161/HYPERTENSIONAHA.121.16975. Epub 2021 May 12. PMID: 33979187.
Copy Download .nbib Format: NLM
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

ESC heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34544205
ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20.

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim...

Cite
Kolwelter J, Bosch A, Jung S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6):5327-5337doi: 10.1002/ehf2.13622.
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, 8(6), 5327-5337. https://doi.org/10.1002/ehf2.13622
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC heart failure vol. 8,6 (2021): 5327-5337. doi: https://doi.org/10.1002/ehf2.13622
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20. PMID: 34544205.
Copy Download .nbib Format: NLM
Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients.

Journal of human hypertension

Nolde JM, Lugo-Gavidia LM, Kannenkeril D, Chan J, Robinson S, Jose A, Joyson A, Schlaich L, Carnagarin R, Azzam O, Kiuchi MG, Schlaich MP.
PMID: 34354250
J Hum Hypertens. 2021 Aug 05; doi: 10.1038/s41371-021-00588-3. Epub 2021 Aug 05.

Recent analysis of systolic inter-arm differences in blood pressure from the INTERPRESS-IPD Collaboration suggest an association with increased all-cause mortality, cardiovascular mortality and cardiovascular events. Previous studies have demonstrated associations with other risk parameters. We aimed to reproduce these...

Cite
Nolde JM, Lugo-Gavidia LM, Kannenkeril D, et al. Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. J Hum Hypertens. 2021;doi: 10.1038/s41371-021-00588-3.
Nolde, J. M., Lugo-Gavidia, L. M., Kannenkeril, D., Chan, J., Robinson, S., Jose, A., Joyson, A., Schlaich, L., Carnagarin, R., Azzam, O., Kiuchi, M. G., & Schlaich, M. P. (2021). Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. Journal of human hypertension, . https://doi.org/10.1038/s41371-021-00588-3
Nolde, Janis M, et al. "Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients." Journal of human hypertension vol. (2021). doi: https://doi.org/10.1038/s41371-021-00588-3
Nolde JM, Lugo-Gavidia LM, Kannenkeril D, Chan J, Robinson S, Jose A, Joyson A, Schlaich L, Carnagarin R, Azzam O, Kiuchi MG, Schlaich MP. Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. J Hum Hypertens. 2021 Aug 05; doi: 10.1038/s41371-021-00588-3. Epub 2021 Aug 05. PMID: 34354250.
Copy Download .nbib Format: NLM
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

ESC heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE.
PMID: 34544205
ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20.

AIMS: Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim...

Cite
Kolwelter J, Bosch A, Jung S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6):5327-5337doi: 10.1002/ehf2.13622.
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S., & Schmieder, R. E. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC heart failure, 8(6), 5327-5337. https://doi.org/10.1002/ehf2.13622
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC heart failure vol. 8,6 (2021): 5327-5337. doi: https://doi.org/10.1002/ehf2.13622
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021 Dec;8(6):5327-5337. doi: 10.1002/ehf2.13622. Epub 2021 Sep 20. PMID: 34544205; PMCID: PMC8712907.
Copy Download .nbib Format: NLM
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.

Cardiovascular diabetology

Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R.
PMID: 34991562
Cardiovasc Diabetol. 2022 Jan 06;21(1):4. doi: 10.1186/s12933-021-01436-x.

BACKGROUND: In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on L-arginine (Arg) related risk markers asymmetric and symmetric dimethylarginine (ADMA and SDMA) and...

Cite
Gessner A, Gemeinhardt A, Bosch A, et al. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022;21(1):4doi: 10.1186/s12933-021-01436-x.
Gessner, A., Gemeinhardt, A., Bosch, A., Kannenkeril, D., Staerk, C., Mayr, A., Fromm, M. F., Schmieder, R. E., & Maas, R. (2022). Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular diabetology, 21(1), 4. https://doi.org/10.1186/s12933-021-01436-x
Gessner, Arne, et al. "Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers." Cardiovascular diabetology vol. 21,1 (2022): 4. doi: https://doi.org/10.1186/s12933-021-01436-x
Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022 Jan 06;21(1):4. doi: 10.1186/s12933-021-01436-x. PMID: 34991562; PMCID: PMC8740418.
Copy Download .nbib Format: NLM
Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes.

Journal of diabetes and its complications

Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Dahlmann A, Kopp C, Schiffer M, Linz P, Nagel AM, Uder M, Schmieder RE.
PMID: 34620556
J Diabetes Complications. 2021 Dec;35(12):108055. doi: 10.1016/j.jdiacomp.2021.108055. Epub 2021 Sep 29.

BACKGROUND: Prospective studies describe a linkage between increased sodium intake and higher incidence of cardiovascular organ damage and end points. We analyzed whether tissue sodium content in the skin and muscles correlate with vascular hypertrophic remodeling, a risk factor...

Cite
Kannenkeril D, Jung S, Harazny J, et al. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021;35(12):108055doi: 10.1016/j.jdiacomp.2021.108055.
Kannenkeril, D., Jung, S., Harazny, J., Striepe, K., Ott, C., Dahlmann, A., Kopp, C., Schiffer, M., Linz, P., Nagel, A. M., Uder, M., & Schmieder, R. E. (2021). Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. Journal of diabetes and its complications, 35(12), 108055. https://doi.org/10.1016/j.jdiacomp.2021.108055
Kannenkeril, Dennis, et al. "Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes." Journal of diabetes and its complications vol. 35,12 (2021): 108055. doi: https://doi.org/10.1016/j.jdiacomp.2021.108055
Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Dahlmann A, Kopp C, Schiffer M, Linz P, Nagel AM, Uder M, Schmieder RE. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021 Dec;35(12):108055. doi: 10.1016/j.jdiacomp.2021.108055. Epub 2021 Sep 29. PMID: 34620556.
Copy Download .nbib Format: NLM
Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes.

Journal of diabetes and its complications

Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Dahlmann A, Kopp C, Schiffer M, Linz P, Nagel AM, Uder M, Schmieder RE.
PMID: 34620556
J Diabetes Complications. 2021 Dec;35(12):108055. doi: 10.1016/j.jdiacomp.2021.108055. Epub 2021 Sep 29.

BACKGROUND: Prospective studies describe a linkage between increased sodium intake and higher incidence of cardiovascular organ damage and end points. We analyzed whether tissue sodium content in the skin and muscles correlate with vascular hypertrophic remodeling, a risk factor...

Cite
Kannenkeril D, Jung S, Harazny J, et al. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021;35(12):108055doi: 10.1016/j.jdiacomp.2021.108055.
Kannenkeril, D., Jung, S., Harazny, J., Striepe, K., Ott, C., Dahlmann, A., Kopp, C., Schiffer, M., Linz, P., Nagel, A. M., Uder, M., & Schmieder, R. E. (2021). Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. Journal of diabetes and its complications, 35(12), 108055. https://doi.org/10.1016/j.jdiacomp.2021.108055
Kannenkeril, Dennis, et al. "Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes." Journal of diabetes and its complications vol. 35,12 (2021): 108055. doi: https://doi.org/10.1016/j.jdiacomp.2021.108055
Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Dahlmann A, Kopp C, Schiffer M, Linz P, Nagel AM, Uder M, Schmieder RE. Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021 Dec;35(12):108055. doi: 10.1016/j.jdiacomp.2021.108055. Epub 2021 Sep 29. PMID: 34620556.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries